Cargando…

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors

Herein we report the structure‐activity and structure‐physicochemical property relationships of a series of class I selective ortho‐aminoanilides targeting the “foot‐pocket” in HDAC1&2. To balance the structural benefits and the physicochemical disadvantages of these substances, we started with...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäker‐Hübner, Linda, Haschemi, Reza, Büch, Thomas, Kraft, Fabian B., Brumme, Birke, Schöler, Andrea, Jenke, Robert, Meiler, Jens, Aigner, Achim, Bendas, Gerd, Hansen, Finn K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303312/
https://www.ncbi.nlm.nih.gov/pubmed/35073610
http://dx.doi.org/10.1002/cmdc.202100755
_version_ 1784751833214877696
author Schäker‐Hübner, Linda
Haschemi, Reza
Büch, Thomas
Kraft, Fabian B.
Brumme, Birke
Schöler, Andrea
Jenke, Robert
Meiler, Jens
Aigner, Achim
Bendas, Gerd
Hansen, Finn K.
author_facet Schäker‐Hübner, Linda
Haschemi, Reza
Büch, Thomas
Kraft, Fabian B.
Brumme, Birke
Schöler, Andrea
Jenke, Robert
Meiler, Jens
Aigner, Achim
Bendas, Gerd
Hansen, Finn K.
author_sort Schäker‐Hübner, Linda
collection PubMed
description Herein we report the structure‐activity and structure‐physicochemical property relationships of a series of class I selective ortho‐aminoanilides targeting the “foot‐pocket” in HDAC1&2. To balance the structural benefits and the physicochemical disadvantages of these substances, we started with a set of HDACi related to tacedinaline (CI‐994) and evaluated their solubility, lipophilicity (log D(7.4)) and inhibition of selected HDAC isoforms. Subsequently, we selected the most promising “capless” HDACi and transferred its ZBG to our previously published scaffold featuring a peptoid‐based cap group. The resulting hit compound 10 c (LSH‐A54) showed favorable physicochemical properties and is a potent, selective HDAC1/2 inhibitor. The following evaluation of its slow binding properties revealed that LSH‐A54 binds tightly to HDAC1 in an induced‐fit mechanism. The potent HDAC1/2 inhibitory properties were reflected by attenuated cell migration in a modified wound healing assay and reduced cell viability in a clonogenic survival assay in selected breast cancer cell lines.
format Online
Article
Text
id pubmed-9303312
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93033122022-07-22 Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors Schäker‐Hübner, Linda Haschemi, Reza Büch, Thomas Kraft, Fabian B. Brumme, Birke Schöler, Andrea Jenke, Robert Meiler, Jens Aigner, Achim Bendas, Gerd Hansen, Finn K. ChemMedChem Research Articles Herein we report the structure‐activity and structure‐physicochemical property relationships of a series of class I selective ortho‐aminoanilides targeting the “foot‐pocket” in HDAC1&2. To balance the structural benefits and the physicochemical disadvantages of these substances, we started with a set of HDACi related to tacedinaline (CI‐994) and evaluated their solubility, lipophilicity (log D(7.4)) and inhibition of selected HDAC isoforms. Subsequently, we selected the most promising “capless” HDACi and transferred its ZBG to our previously published scaffold featuring a peptoid‐based cap group. The resulting hit compound 10 c (LSH‐A54) showed favorable physicochemical properties and is a potent, selective HDAC1/2 inhibitor. The following evaluation of its slow binding properties revealed that LSH‐A54 binds tightly to HDAC1 in an induced‐fit mechanism. The potent HDAC1/2 inhibitory properties were reflected by attenuated cell migration in a modified wound healing assay and reduced cell viability in a clonogenic survival assay in selected breast cancer cell lines. John Wiley and Sons Inc. 2022-02-18 2022-05-04 /pmc/articles/PMC9303312/ /pubmed/35073610 http://dx.doi.org/10.1002/cmdc.202100755 Text en © 2022 The Authors. ChemMedChem published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Schäker‐Hübner, Linda
Haschemi, Reza
Büch, Thomas
Kraft, Fabian B.
Brumme, Birke
Schöler, Andrea
Jenke, Robert
Meiler, Jens
Aigner, Achim
Bendas, Gerd
Hansen, Finn K.
Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
title Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
title_full Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
title_fullStr Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
title_full_unstemmed Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
title_short Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
title_sort balancing histone deacetylase (hdac) inhibition and drug‐likeness: biological and physicochemical evaluation of class i selective hdac inhibitors
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303312/
https://www.ncbi.nlm.nih.gov/pubmed/35073610
http://dx.doi.org/10.1002/cmdc.202100755
work_keys_str_mv AT schakerhubnerlinda balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT haschemireza balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT buchthomas balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT kraftfabianb balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT brummebirke balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT scholerandrea balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT jenkerobert balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT meilerjens balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT aignerachim balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT bendasgerd balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors
AT hansenfinnk balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors